Tayebi N, Stern H, Dymarskaia I, Herman J, Sidransky E
Clinical Neuroscience Branch, National Institute of Mental Health, NIH, Bethesda, MD 20892-4405, USA.
Am J Med Genet. 1996 Dec 18;66(3):316-9. doi: 10.1002/(SICI)1096-8628(19961218)66:3<316::AID-AJMG15>3.0.CO;2-P.
Mutations in the glucocerebrosidase gene which result in Gaucher disease can originate from the highly homologous glucocerebrosidase pseudogene. A 55-bp deletion in exon 9, which corresponds to a 55-bp segment absent from the pseudogene, has been identified in patients with Gaucher disease. We have developed a simple polymerase chain reaction (PCR)-based method to detect this 55-bp deletion, and have found this mutation in 3 of 75 DNA samples (4%) collected from patients with Gaucher disease. Commonly used PCR-based screening methods for specific Gaucher mutations frequently make use of primers either within or surrounding the 55-bp gap to selectively distinguish the glucocerebrosidase gene from the pseudogene. However, if the 55-bp deletion in exon 9 occurs, primers will either fail to produce an amplification product or will produce a shortened product which will be falsely attributed to the pseudogene. This could lead to inaccurate genotyping and genetic counseling for some Gaucher patients and their families. We therefore recommended that laboratories using PCR-based screening techniques involving primers in this region initially determine whether this 55-bp sequence is present.
导致戈谢病的葡萄糖脑苷脂酶基因突变可能源自高度同源的葡萄糖脑苷脂酶假基因。在戈谢病患者中已鉴定出第9外显子中有一个55 bp的缺失,该缺失对应于假基因中不存在的一个55 bp片段。我们开发了一种基于聚合酶链反应(PCR)的简单方法来检测这种55 bp的缺失,并在从戈谢病患者收集的75个DNA样本中的3个(4%)中发现了这种突变。常用的基于PCR的特定戈谢突变筛查方法通常利用55 bp缺口内部或周围的引物来选择性地将葡萄糖脑苷脂酶基因与假基因区分开来。然而,如果第9外显子中出现55 bp的缺失,引物要么无法产生扩增产物,要么会产生一个缩短的产物,该产物会被错误地归因于假基因。这可能导致一些戈谢病患者及其家属的基因分型不准确和遗传咨询出现问题。因此,我们建议使用涉及该区域引物的基于PCR的筛查技术的实验室首先确定该55 bp序列是否存在。